Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

760

Figures (1-4)

140

Sum=1003

Publishing Process of This Article

Item

Count

Browse

100

Download

252

Sum=352

Dec 16, 2023 (publication date) through Aug 27, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Dec 16, 2023; 11(35): 8385-8391
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8385

Full Size Figure Download Figure

Figure 1 A 7. 2 cm × 9.7 cm cystic solid density shadow was seen in the left upper abdominal cavity.

Citation: Wu RT, Zhang JC, Fang CN, Qi XY, Qiao JF, Li P, Su L. Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report. World J Clin Cases 2023; 11(35): 8385-8391
URL: https://www.wjgnet.com/2307-8960/full/v11/i35/8385.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i35.8385